Company intelligence / Profile preview

Innosys

Ownership: Private
Development stage: Commercial

Overview

Innosys has developed and commercialized advanced orthopedic devices, including a 3D printed titanium cervical cage ("Unispace") for spinal fusion, which received FDA 510(k) clearance in April 2024 and has been successfully implanted in US patients. The company also recently launched injectable bone graft substitutes ("Velofuse Gel" and "Velofuse Putty").

Therapeutic areas: OtherNeurology
Modalities: Device3D printed device
Industry: Implantable Medical Devices

Partnerships

Zimmer SpineWright MedicalCG Bio

Beyond the preview

Go deeper on Innosys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innosys.

Explore the full profile